Blackstone-backed Catalent sets terms for $871 million IPO

Comment

Shutterstock photo

Catalent, a global provider of oral, injectable and respiratory drug delivery technologies, announced terms for its IPO on Friday. The Somerset, NJ-based company plans to raise $871 million by offering 42.5 million shares at a price range of $19 to $22. At the midpoint of the proposed range, Catalent would command a fully diluted market value of $2.5 billion.

Catalent is the former Performance Technologies and Services segment of Cardinal Health ( CAH ), which Blackstone ( BX ) acquired for $3.3 billion in 2007. The company produces more than 70 billion doses for nearly 7,000 customer products annually. Key customers include Pfizer, Johnson & Johnson, GlaxoSmithKline, Merck, Novartis, Roche, Actavis and Teva.

Catalent, which was founded in 2007 and booked $1.8 billion in sales for the 12 months ended March 31, 2014, plans to list on the NYSE under the symbol CTLT. Morgan Stanley, J.P. Morgan, BofA Merrill Lynch, Goldman Sachs, Jefferies and Deutsche Bank are the joint bookrunners on the deal. It is expected to price during the week of July 28, 2014.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs
More Headlines for: CAH , BX , CTLT


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com